Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Genomics BioSci & Tech Co's share price is NT$15.35.
Genomics BioSci & Tech Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was NT$10.15. Hence, Genomics BioSci & Tech Co's PS Ratio for today is 1.51.
Good Sign:
Genomics BioSci & Tech Co Ltd stock PS Ratio (=1.51) is close to 2-year low of 1.5.
The historical rank and industry rank for Genomics BioSci & Tech Co's PS Ratio or its related term are showing as below:
TPE:4195'
s PS Ratio Range Over the Past 10 Years
Min: 1.5 Med: 2.9 Max: 10.32
Current: 1.51
During the past 13 years, Genomics BioSci & Tech Co's highest PS Ratio was 10.32. The lowest was 1.50. And the median was 2.90.
TPE:4195's PS Ratio is ranked better than 87.84% of 929
companies
in the Biotechnology industry
Industry Median: 9.49
vs TPE:4195: 1.51
During the past 12 months, the average Revenue per Share Growth Rate of Genomics BioSci & Tech Co was 79.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 14.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 4.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 1.30% per year.
During the past 13 years, Genomics BioSci & Tech Co's highest 3-Year average Revenue per Share Growth Rate was 20.10% per year. The lowest was -25.00% per year. And the median was 1.40% per year.
Genomics BioSci & Tech Co (TPE:4195) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Genomics BioSci & Tech Co PS Ratio Related Terms
Genomics BioSci & Tech Co PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Genomics BioSci & Tech Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomics BioSci & Tech Co PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genomics BioSci & Tech Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Genomics BioSci & Tech Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Genomics BioSci & Tech Co's Share Price of today is NT$15.35. Genomics BioSci & Tech Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$10.15.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Genomics BioSci & Tech Co (TPE:4195) has a PS Ratio of 1.51 as of Aug. 09, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Genomics BioSci & Tech Co and its competitors. This is 48% below median its historical median of 2.90. Over the past decade, Genomics BioSci & Tech Co's PS Ratio has ranged from 1.50 to 10.32. According to the industry distribution chart, Genomics BioSci & Tech Co ranks #113 out of 929 companies in the Biotechnology industry, placing it in the top 12.2%.
Is Genomics BioSci & Tech Co's PS Ratio too high?
Genomics BioSci & Tech Co's current PS Ratio of 1.51 is 48% below median its 10-year median of 2.90. Over the past 10 years, this metric has ranged from a low of 1.50 to a high of 10.32. The Biotechnology industry median PS Ratio is 9.49. Genomics BioSci & Tech Co's value of 1.51 is 84.1% below this industry median. Based on the distribution chart, Genomics BioSci & Tech Co ranks #113 out of 929 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genomics BioSci & Tech Co has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Genomics BioSci & Tech Co's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genomics BioSci & Tech Co ranks #113 out of 929 companies for PS Ratio. This places Genomics BioSci & Tech Co in the top 12% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.49. Genomics BioSci & Tech Co's value of 1.51 is 84.1% below this benchmark. Historically, Genomics BioSci & Tech Co's own PS Ratio has ranged from 1.50 to 10.32 over the past decade. While the company's 10-year median is 2.90 vs. the industry median of 9.49, Genomics BioSci & Tech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.49, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomics BioSci & Tech Co's current PS Ratio of 1.51 is 84.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Genomics BioSci & Tech Co and its competitors. For the Biotechnology industry, the median PS Ratio is 9.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomics BioSci & Tech Co's current PS Ratio is 1.51, which is 48% below median its own 10-year median of 2.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomics BioSci & Tech Co stock overvalued right now?
Based on GuruFocus' analysis, Genomics BioSci & Tech Co (TPE:4195) is currently considered Possible Value Trap. The stock's GF Value™ is NT$34.60, compared to a current price of NT$15.35 — trading 55.6% below its estimated fair value. The current PS Ratio is 1.51, which is 48% below median its 10-year median of 2.90 and 84.1% below the Biotechnology industry median of 9.49. Genomics BioSci & Tech Co's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Genomics BioSci & Tech Co (TPE:4195), the current PS Ratio is 1.51 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomics BioSci & Tech Co (TPE:4195) Overvalued in 2026?
Based on GuruFocus' analysis, Genomics BioSci & Tech Co stock appears to be undervalued.
The current stock price of NT$15.35 is trading 55.6% below its estimated GF Value™ of NT$34.60.
GuruFocus considers Genomics BioSci & Tech Co to be Possible Value Trap.
Key valuation signals for TPE:4195:
PS Ratio: 1.51 (48% below median its 10-year median of 2.90)
GF Value™: NT$34.60 vs. price of NT$15.35 (55.6% below fair value)
Industry Position: 84.1% below the Biotechnology median (#113 of 929)
No single metric tells the full story. See the TPE:4195 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomics BioSci & Tech Co Ltd is a Taiwan based commercial genome sequencing company formed to develop medical genetic testing. The services of the company include Sanger sequence service, Synthesis Service and Genomic Service.
42GF Score
Get the complete analysis for TPE:4195
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4195 has been successfully added to your 
